• 1
    Yerby MS, Teratogenic effects of antiepileptic drugs: what do we advise patients Epilepsia 1997;38:9578.
  • 2
    Lindhout D, Omtzigt JGC, Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994;35:S1928.
  • 3
    Lindhout D, Meinardi H, Meijer JW, et al. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992;42(suppl 5):94110.
  • 4
    Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:98190.
  • 5
    Dravet C, Julian C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992;42(suppl 5):7582.
  • 6
    Källén B., Search for teratogenic risks with the aid of malformation registries. Teratology 1987;35:4752.
  • 7
    Robert E, Vollset SE, Botto L, et al. Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Safety Med 1994;6:75118.
  • 8
    International Clearinghouse for Birth Defects Monitoring Systems. Congenital malformations worldwide. Amsterdam , The Netherlands : Elsevier Science Publishers, 1991.
  • 9
    World Health Organization. Manual of International Statistical Classification of Diseases, Injures and Causes of Deaths: Based on recommendations of the 9th Revision Conference, 1975, and adopted by the 29th World Health Assembly. Geneva , Switzerland : World Health Organization, 1977.
  • 10
    World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC Index including DDDs for plain substances. Geneva , Switzerland : World Health Organization, 1990.
  • 11
    Breslow NE, Day NE, Statistical methods in cancer research, vol. 1: The analysis of case-control studies. Lyon , France : IARC, 1980:Scientific publication no. 32.
  • 12
    Mantel N, Haenszel W., Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:71948.
  • 13
    Zelen M., The analysis of several 2 × 2 contingency tables. Biometrika 1971;58:12937.
  • 14
    Gart J., Point and interval estimation of the common odds ratio in the combination of 2 × 2 tables with fixed marginals. Biometrika 1970;57:47175.
  • 15
    Miettinen OS, Theoretical epidemiolgy: principles of occurrence in research in medicine. New York , NY : John Wiley & Sons, 1985.
  • 16
    Mehta CR, Walsh JS, Comparison of exact, mid-p, and Mantel-Haenszel confidence intervals for common odds ratio across several 2 × 2 contingency tables. Am Stat 1992;46:14650.
  • 17
    Robert E, Guibaud P., Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937.
  • 18
    Mastroiacovo P, Bertollini R, Morandini S, et al. Maternal epilepsy, valproate exposure and birth defects. Lancet 1983;2:1499.
  • 19
    Lindhout D, Meinardi H., Spina bifida and in-utero exposure to valproate. Lancet 1984;2:396.
  • 20
    Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992;42(suppl 5):11925.
  • 21
    Lindhout D, Omtzigt JGC, Cornel MC, Spectrum of neural tube defects in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(suppl 5):1118.
  • 22
    Källén AJ, Maternal carbamazepine and infant spina bifida. Reprod Toxicol 1994;8:2035.
  • 23
    Rosa FW, Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:6747.
  • 24
    Nau H., Valproic acid and teratogenicity in mice after various administration and phenobarbital-pretreatment regimens: the parent drug and not one of the metabolites assayed is implicated as teratogen. Fundam Appl Toxicol 1986;6:6628.
  • 25
    Lindhout D, Schmidt D., In-utero exposure to valproate and neural tube defects. Lancet 1986;1:13923.
  • 26
    Lander CM, Eadie MJ, Antiepileptic drug intake during pregnancy and malformed offspring. Epilepsy Res 1990;7:7782.
  • 27
    Di Liberti JH, Farndon PA, Derms NR, The fetal valproic syndrome. Am J Med Genet 1984;19:4734.
  • 28
    Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989;320:16616.
  • 29
    Robert E, Jouk PS, Preaxial limb defects after valproic acid exposure during pregnancy. In: MastroiacovoP, KällénB, CastillaE, eds. Proceedings of the First International Meeting of the Genetic and Reproductive Epidemiology Research Society (GRERS). Rome : Ghedini Editore, 1992:1015.
  • 30
    Sharony R, Garber A, Viskochil D, et al. Preaxial ray reduction defects as part of valproic acid embryofetopathy. Prenat Diagn 1993;13:90918.